Karuna Therapeutics, Inc.
NASDAQ: KRTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William Meury
- Employees
- 339
- Headquarters
- Boston, United States
- IPO year
- 2019
- Market cap
- $12.6B
- Website
- https://www.karunatx.com
Loading KRTX…
Loading profile data…Frequently asked questions about KRTX
What does Karuna Therapeutics, Inc. (KRTX) do?
Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT...
Where does KRTX trade?
Karuna Therapeutics, Inc. (KRTX) trades on the NASDAQ Global Market.
What sector is KRTX in?
Karuna Therapeutics, Inc. (KRTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Karuna Therapeutics, Inc.?
William Meury is the chief executive officer of Karuna Therapeutics, Inc. (KRTX).
Where is Karuna Therapeutics, Inc. headquartered?
Karuna Therapeutics, Inc. is headquartered in United States.
Does KRTX pay a dividend?
Karuna Therapeutics, Inc. (KRTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KRTX go public?
Karuna Therapeutics, Inc. (KRTX) completed its initial public offering in 2019.